4.3.1 Sintesi e raccomandazioni - Biblioteca Medica

23. Os I, Stokke HP. : Doxazosin GITS compared with doxazosin standard and placebo in
patients with mild hypertension. Blood Press. 1999;8(3):184-91.
24. Chung M, Vashi V, Puente J, Sweeney M, Meredith P. : Clinical pharmacokinetics of
doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation.
Br J Clin Pharmacol. 1999 Nov;48(5):678-87.
25. Schulman CC, Cortvriend J, Jonas U, Lock TM, Vaage S, Speakman MJ. : Tamsulosin:
3-year long-term efficacy and safety in patients with lower urinary tract symptoms
suggestive of benign prostatic obstruction: analysis of a European, multinational,
multicenter, open-label study. European Tamsulosin Study Group. Eur Urol. 1999
Dec;36(6):609-20.
26. MacDiarmid SA, Emery RT, Ferguson SF, McGuirt-Franklin R, McIntyre WJ, Johnson
DE.: A randomized double-blind study assessing 4 versus 8 mg. doxazosin for benign
prostatic hyperplasia. J Urol. 1999 Nov;162(5):1629-32.
27. McNeill SA, Daruwala PD, Mitchell ID, Shearer MG, Hargreave TB. : Sustained-release
alfuzosin and trial without catheter after acute urinary retention: a prospective, placebocontrolled.
BJU Int. 1999 Oct;84(6):622-7.
28. Fawzy A, Hendry A, Cook E, Gonzalez F. : Long-term (4 year) efficacy and tolerability of
doxazosin for the treatment of concurrent benign prostatic hyperplasia and hypertension.
Int J Urol. 1999 Jul;6(7):346-54.
29. Lowe FC, Olson PJ, Padley RJ. : Effects of terazosin therapy on blood pressure in men
with benign prostatic hyperplasia concurrently treated with other antihypertensive
medications.Urology. 1999 Jul;54(1):81-5.
30. Wyllie MG. : alpha1-adrenoceptor selectivity: the North American experience. Eur Urol.
1999;36 Suppl 1:59-63; discussion 65.
31. Os I, Stokke HP. : Effects of doxazosin in the gastrointestinal therapeutic system
formulation versus doxazosin standard and placebo in mild-to-moderate hypertension.
Doxazosin Investigators’ Study Group. J Cardiovasc Pharmacol. 1999 May;33(5):791-
7.
32. Fawzy A, Vashi V, Chung M, Dias N, Gaffney M. : Clinical correlation of maximal
urinary flow rate and plasma doxazosina concentrations in the treatment of benign
prostatic hyperplasia. MulticenterStudy Group. Urology. 1999 Feb;53(2):329-35.
33. Vashi V, Chung M, Hilbert J, Lawrence V, Phillips K. : Pharmacokinetic interaction
between finasteride and terazosin, but not finasteride and doxazosin. J Clin Pharmacol.
1998 Nov;38(11):1072-6.
34. Gerdts E, Svarstad E, Aanderud S, Myking OL, Lund-Johansen P, Omvik P. : Factors
influencing reduction in blood pressure and left ventricular mass in hypertensive type-
1 diabetic patients using captopril or doxazosin for 6 months. Am J Hypertens. 1998
Oct;11(10):1178-87.
35. Narayan P, Tewari A. : A second phase III multicenter placebo controlled study of 2
dosages ofmodified release tamsulosin in patients with symptoms of benign prostatic
hyperplasia. United States 93-01 Study Group. J Urol. 1998 Nov;160(5):1701-6.
36. Kirby RS. : Terazosin in benign prostatic hyperplasia: effects on blood pressure in
normotensive and hypertensive men. Br J Urol. 1998 Sep;82(3):373-9.
160